BioBill

Gene therapy analyst

[BioBill @BioBill2]

@HealthcareNinj1 @Overlevered_AM Hopefully prmt5 inhibitor can synergies with g12c in clinic.

[BioBill @BioBill2]

@jmbiofarm Hahah, we picked the same 😂. I feel yuh on this…

[BioBill @BioBill2]

@reco_plasmid https://t.co/CAoOSu4TeO some relevant information. I’m also interested in $LVTX.

[BioBill @BioBill2]

@MSollender $acet 1H 2022 additional data.

[BioBill @BioBill2]

@gamechangercap @Biotech2k1 Irak4 and hpk1. Both seem to be gilead targets. Arvinas also has an hpk1 protac in research and an irak4 protac is being developed by kymr/sanofi.

[BioBill @BioBill2]

@Biotech2k1 They have some early Kras development, I’m sure you’d be interested in following.

[BioBill @BioBill2]

@bigpharmaguy When I’m on Hulu every other commercial is drugs drugs drugs 😂

[Pengyu Yang @Pengyu19]

Identification of #MRTX1133, a Noncovalent, Potent, and Selective #KRASG12D Inhibitor https://t.co/okfd6b8pJl

[BioBill @BioBill2]

@Mykalt45 @ohadhammer @TheATGCSeeker Yep! That’s my horse in the race.

[BioBill @BioBill2]

@ohadhammer @TheATGCSeeker @Mykalt45 I think the MTA cooperative prmt5 inhibitors can open the therapeutic window for MTAP. Amgen just started enrolling patients for theirs.

[BioBill @BioBill2]

$BPMC looking to start a position. Really excited for early look at BLU-701 and BLU-945. I like the combination idea to drive deep and and durable responses, potentially covering multiple acquired resistance mutations. Along with the ability to control CNS metastasis.

[BioBill @BioBill2]

@adsorb87210870 @onlybios No

[BioBill @BioBill2]

@BioWino @Sanctuary_Bio @retailbiotech Crazy how you have a company like $lyel that has 900m in cash with a GSK partnership and a pre clinical ror1 car targeting TNBC and NSCLC🤔. 2B MC… 50% off ATH… not a much talked about name. Interesting story that’s for sure.

[BioBill @BioBill2]

@IceBear873 @BioValues He’s talkin about you👀

[BioBill @BioBill2]

@JRMKE3 @brendan_49 Thanks, I’ll check it out.

[BioBill @BioBill2]

@JRMKE3 @brendan_49 I remember when they announced first patient dosed it was r/r ALL at 90M cells. Is there a specific call or report they discuss that dosing reg you speak of ?